# Impact of Hyperoncotic Albumin to Support Blood Loss Replacement

> **NCT03848507** · PHASE4 · COMPLETED · sponsor: **Insel Gruppe AG, University Hospital Bern** · enrollment: 24 (actual)

## Conditions studied

- Blood Loss, Surgical
- Fluid Retention

## Interventions

- **DRUG:** albumin 20%

## Key facts

- **NCT ID:** NCT03848507
- **Lead sponsor:** Insel Gruppe AG, University Hospital Bern
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-03-18
- **Primary completion:** 2020-02-12
- **Final completion:** 2020-02-18
- **Target enrollment:** 24 (ACTUAL)
- **Last updated:** 2020-02-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03848507

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03848507, "Impact of Hyperoncotic Albumin to Support Blood Loss Replacement". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT03848507. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*